Hal Barron, GlaxoSmithKline president of R&D (Endpoints file photo)

Bil­lions on the ta­ble, GSK’s Hal Bar­ron antes $120M cash to part­ner with a spe­cial­ist in syn­thet­ic lethal­i­ty

GSK R&D chief Hal Bar­ron has turned to an­oth­er Bay Area biotech for his lat­est on­col­o­gy drug de­vel­op­ment pact, which could to­tal bil­lions for a pre­clin­i­cal deal that starts with $120 mil­lion in cash. And this one speaks di­rect­ly to one of his fa­vorite top­ics: syn­thet­ic lethal­i­ty.

Bar­ron is part­ner­ing with Ideaya Bio­sciences $IDYA for this new al­liance. GSK is hand­ing over $100 mil­lion in up­front cash, plus an­oth­er $20 mil­lion for a chunk of stock.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.